Scores by echosens
Enhance FibroScan® liver disease assessment with biological markers
Improve reliability in the diagnosis and monitoring of steatosis
With SmartExam, a new computation method allows continuous measurement of CAP™ during the entire examination. In addition, when CAP™ measurement doesn’t meet the quality criteria they are automatically rejected.
SmartExam with Continuous CAP™ decreases variability by 42%.1
Continuous CAP™ can be measured on children with FibroScan® S probe to prevent them from undergoing biopsy.
Extend usage among severely obese patients
With SmartExam, the maximum recommended PCD (Probe to Capsula Distance) is 45 mm (vs 35 mm without SmartExam) representing an increase of 28%.
These task automation features were designed to further enhance the standardization of the FibroScan® examination.
SmartExam is available as an option.
SmartExam is a key technology for improving standardization of FibroScan® and eliminate liver stiffness and CAP™ measurements bias caused by the long probe-to-capsule distance in patients with obesity; thus, it increases the diagnostic accuracy and reliability to identify fatty liver and assess fibrosis in this clinical population.
The obese population that we receive for FibroScan® examinations has increased substantially in recent years. CAP™ has become essential to our prescribers to precisely monitor patient’s steatosis. SmartExam allows us to address difficult patients and to provide reliable results to our prescribers.
1. Audière et al. EASL 2020 poster #FRI-073. 42% is the variability decrease computed on patient’s cohort scanned with the M probe.
FibroScan® Indications for Use
The FibroScan® Family of Products (models: Compact 530, Mini+ 430 and Expert 630) is intended to provide shear wave speed measurements and estimates of tissue stiffness as well as ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body. The Shear wave speed and stiffness measurements may be used as an aid to clinical management of adult patients with liver disease.
The FibroScan® 630 is indicated for non-invasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as determining a 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter). The shear wave speed and stiffness, and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver. Shear wave speed and stiffness, and CAP* may be used as an aid in the clinical management of pediatric patients with liver disease. FibroScan® 630 (Expert) is also indicated for noninvasive measurement in the spleen of 100 Hz shear wave speed and estimates of stiffness that may be used as an aid to diagnosis, monitoring and clinical management of adult patients with liver disease, as part of an overall assessment of the liver.
* CAP for pediatric patients with liver disease is only available with SmartExam capability.
FAST and Interpretation Guide are Non-Device CDS (Clinical Decision Support) that meet all parts of the 4 sections 520(o)(1)(E) criteria.